Brits Lead Charge In Global Battle Against Antimicrobial Resistant Superbugs

During the annual BIO International conference in June, researchers from the UK – which has pushed antimicrobial resistance to front and center on the global stage – discussed ongoing efforts for incentivizing antibiotic discovery and development, and the challenges that remain when it comes to management and resolution of the world’s AMR crisis.

Tackling an unmet need is a common focus for pharmaceutical companies when choosing the therapeutic areas they will concentrate on – but it is often not enough. Pharma business executives have also got to be able to see a clear route to returns on their investments. While no one doubts the huge medical challenge antimicrobial resistance (AMR) poses, how to incentivize companies to work on solutions is proving to be more difficult. During BIO 2018, held in Boston, June 4-7, researchers from the UK discussed what efforts were being made to devise incentivization models.

The numbers verge on the apocalyptic. Currently, more than 50,000 people a year in the EU and US die from an antimicrobial resistant infection, often contracted when at the hospital...

More from Innovation

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.